[Featured Stock] "Nationwide Diagnostic Service in the US" Somagen... Hits Upper Limit

[Asia Economy Reporter Lee Seon-ae] On the 29th, Somagen entered the upper price limit. This is interpreted as benefiting from the emergence of the new COVID-19 variant 'Omicron'.

Somagen, which started at 8,250 won that day, is trading at 10,400 won (upper limit), up 29.84% as of 9:30 AM.

This is interpreted as an effect of Omicron spreading worldwide, starting from Africa to Europe, Canada, and other regions. Omicron was first reported by South African scientists who discovered a new variant with 32 genetic mutations in the spike protein. WHO designated Omicron as the fifth variant of concern following Alpha, Beta, Gamma, and Delta.

Meanwhile, Somagen launched the 'SalivaDirect COVID-19 At-Home Collection Diagnostic Service' in the United States, allowing people to take COVID-19 tests at home during the pandemic. After purchasing the diagnostic kit from Somagen, users collect saliva and send it back to Somagen's CLIA lab. Accurate test results can be received at home within 1 to 2 days. Anyone aged 18 or older residing in the United States can use this service.

The diagnostic service was developed by the Yale School of Public Health in the United States and received Emergency Use Authorization from the U.S. Food and Drug Administration in April. The company has a licensing agreement with Yale University.

This content was produced with the assistance of AI translation services.